Please login to the form below
Iptacopan
This page shows the latest Iptacopan news and features for those working in and with pharma, biotech and healthcare.
Novartis’ iptacopan scores positive results in rare blood disorder PNH
New treatment options are needed, and these positive results further strengthen the profile of iptacopan as a promising oral monotherapy. ... At the highest dose of 200mg twice daily, a 23% reduction in proteinuria was predicted with iptacopan treatment
Latest news
-
Novartis receives FDA breakthrough therapy designation for rare disease med
Swiss pharma company Novartis has received a breakthrough therapy designation (BTD) for its experimental medication iptacopan for the rare blood disorder paroxysmal nocturnal hemoglobinuria (PNH). ... Iptacopan is the most advanced asset in our
More from news
Approximately 2 fully matching, plus 0 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
-
B2B media account director
-
Competitive salary
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- First trial of a vaccine against Alzheimer’s launches
- First von Willebrand disease therapy heads new FDA approvals
- Sanofi to buy acne specialist Origimm
- US government to pay $5.3bn for Pfizer‘s Paxlovid
- David Hunt launches independent agency The Considered
PMHub
foxandcat.online
some pressure is helpful but too much of the wrong sort quickly takes its toll. we help creatove agenices manage...
Latest intelligence
- Diversity in clinical trials: looking back at our 2021 blogs
- In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
- What does the future hold for Light-chain Amyloidosis?
- Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
- Webinar:
- Securing a future for telehealth with immersive market research insights...
